Sakurai Kenji, Akiyama Hideo, Shimoda Yukitoshi, Yoshida Izumi, Kurabayashi Masahiko, Kishi Shoji
Department of Ophthalmology, Gunma University School of Medicine, Gunma, Japan.
Invest Ophthalmol Vis Sci. 2009 Oct;50(10):4905-16. doi: 10.1167/iovs.07-1542. Epub 2009 Apr 30.
To evaluate the ocular complications of intravitreal injection of high dose bevacizumab in monkey eyes.
Four healthy monkeys (Macaca fuscata) received an intravitreal injection of either 6.25 or 12.5 mg bevacizumab in the right eye; the left control eye received an intravitreal injection of the same volume of saline. The eyes were examined using slit lamp and funduscopy, optical coherence tomography (OCT), electroretinography (ERG), fundus photography (FP), fluorescein angiography (FA), and indocyanine green angiography (ICGA). The eyes were enucleated 28 days after the intravitreal injection and subjected to light microscopy.
No pathologic changes were observed by FP, FA, ICGA, OCT, and light microscopy in the eyes injected with either of the two bevacizumab doses. ERG showed no toxic change in the eyes that received the 6.25-mg dose. In two eyes that received the 12.5-mg dose, ERG showed no significant difference between the right and left eyes 4 weeks after injection, although there were transient changes in scotopic responses.
No irreversible toxic effects were observed in monkey eyes receiving an intravitreal injection of high dose bevacizumab.
评估玻璃体内注射高剂量贝伐单抗对猴眼的眼部并发症。
4只健康猕猴（食蟹猴）右眼接受6.25毫克或12.5毫克贝伐单抗的玻璃体内注射；左眼作为对照，接受相同体积的生理盐水玻璃体内注射。使用裂隙灯、眼底镜检查、光学相干断层扫描（OCT）、视网膜电图（ERG）、眼底照相（FP）、荧光素血管造影（FA）和吲哚菁绿血管造影（ICGA）对眼睛进行检查。玻璃体内注射28天后摘除眼球并进行光学显微镜检查。
接受两种贝伐单抗剂量注射的眼睛，FP、FA、ICGA、OCT和光学显微镜检查均未观察到病理变化。接受6.25毫克剂量的眼睛，ERG未显示毒性变化。在接受12.5毫克剂量的两只眼睛中，注射后4周ERG显示右眼和左眼之间无显著差异，尽管暗视反应有短暂变化。
在接受玻璃体内注射高剂量贝伐单抗的猴眼中未观察到不可逆的毒性作用。
Zotero 插件